Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands

被引：0
|
作者：
Heisen, M.
Treur, M. J.
van der Hel, W. S.
Groot, M. T.
Verheggen, B. G.
机构：
[1] Pharmerit Europe, Rotterdam, Netherlands
[2] Novartis Pharma BV, Arnhem, Netherlands
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [41] Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
    Sharmin, Sifat
    Lefort, Mathilde
    Andersen, Johanna Balslev
    Leray, Emmanuelle
    Horakova, Dana
    Havrdova, Eva Kubala
    Alroughani, Raed
    Izquierdo, Guillermo
    Ozakbas, Serkan
    Patti, Francesco
    Onofrj, Marco
    Lugaresi, Alessandra
    Terzi, Murat
    Grammond, Pierre
    Grand'Maison, Francois
    Yamout, Bassem
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Boz, Cavit
    Trojano, Maria
    McCombe, Pamela
    Slee, Mark
    Lechner-Scott, Jeannette
    Turkoglu, Recai
    Sola, Patrizia
    Ferraro, Diana
    Granella, Franco
    Prevost, Julie
    Maimone, Davide
    Skibina, Olga
    Buzzard, Katherine
    Van der Walt, Anneke
    Van Wijmeersch, Bart
    Csepany, Tunde
    Spitaleri, Daniele
    Vucic, Steve
    Casey, Romain
    Debouverie, Marc
    Edan, Gilles
    Ciron, Jonathan
    Ruet, Aurelie
    De Seze, Jerome
    Maillart, Elisabeth
    Zephir, Helene
    Labauge, Pierre
    Defer, Gilles
    Lebrun-Frenay, Christine
    Moreau, Thibault
    Berger, Eric
    CNS DRUGS, 2021, 35 (11) : 1217 - 1232
  • [42] Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
    Sifat Sharmin
    Mathilde Lefort
    Johanna Balslev Andersen
    Emmanuelle Leray
    Dana Horakova
    Eva Kubala Havrdova
    Raed Alroughani
    Guillermo Izquierdo
    Serkan Ozakbas
    Francesco Patti
    Marco Onofrj
    Alessandra Lugaresi
    Murat Terzi
    Pierre Grammond
    Francois Grand’Maison
    Bassem Yamout
    Alexandre Prat
    Marc Girard
    Pierre Duquette
    Cavit Boz
    Maria Trojano
    Pamela McCombe
    Mark Slee
    Jeannette Lechner-Scott
    Recai Turkoglu
    Patrizia Sola
    Diana Ferraro
    Franco Granella
    Julie Prevost
    Davide Maimone
    Olga Skibina
    Katherine Buzzard
    Anneke Van der Walt
    Bart Van Wijmeersch
    Tunde Csepany
    Daniele Spitaleri
    Steve Vucic
    Romain Casey
    Marc Debouverie
    Gilles Edan
    Jonathan Ciron
    Aurélie Ruet
    Jérôme De Sèze
    Elisabeth Maillart
    Hélène Zephir
    Pierre Labauge
    Gilles Defer
    Christine Lebrun-Frénay
    Thibault Moreau
    Eric Berger
    CNS Drugs, 2021, 35 : 1217 - 1232
  • [43] Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts
    Sharmin, Sifat
    Lefort, Mathilde
    Andersen, Johanna Balslev
    Leray, Emmanuelle
    Horakova, Dana
    Havrdova, Eva
    Alroughani, Raed
    Ayuso, Guillermo Izquierdo
    Ozakbas, Serkan
    Patti, Francesco
    Onofrj, Marco
    Lugaresi, Alessandra
    Terzi, Murat
    Grammond, Pierre
    Grand'Maison, Francois
    Yamout, Bassem
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Boz, Cavit
    Trojano, Maria
    McCombe, Pamela
    Slee, Mark
    Lechner-Scott, Jeannette
    Turkoglu, Recai
    Sola, Patrizia
    Ferraro, Diana
    Granella, Franco
    Prevost, Julie
    Maimone, Davide
    Skibina, Olga
    Buzzard, Katherine
    Van der Walt, Anneke
    Van Wijmeersch, Bart
    Csepany, Tunde
    Spitaleri, Daniele Litterio A.
    Vucic, Ostoja
    Casey, Romain
    Debouverie, Marc
    Edan, Gilles
    Ciron, Jonathan
    Ruet, Aurelie
    De Seze, Jerome
    Maillart, Elisabeth
    Zephir, Helene
    Labauge, Pierre
    Defer, Gilles
    Lebrun-Frenay, Christine
    Moreau, Thibault
    Berger, Eric
    NEUROLOGY, 2021, 96 (15)
  • [44] Fingolimod is cost-saving compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis: a cost-minimisation analysis in Sweden
    Bergvall, N.
    Tambour, M.
    Henriksson, F.
    Fredrikson, S.
    JOURNAL OF NEUROLOGY, 2012, 259 : S69 - S69
  • [45] Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab
    Laursen, Julie Hejgaard
    Sondergaard, Helle Bach
    Sorensen, Per Soelberg
    Sellebjerg, Finn
    Oturai, Annette Bang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 10 : 169 - 173
  • [46] Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    NEUROLOGIA, 2014, 29 (04): : 210 - 217
  • [47] Pharmacogenomic predictors of fingolimod response in relapsing-remitting multiple sclerosis
    Campagna, M. P.
    Stankovich, J.
    Zhong, M.
    Kleinova, P.
    Matesanz, F.
    Eichau, S.
    Slee, M.
    Kilpatrick, T.
    Kubala Havrdova, E.
    Izquierdo, G.
    Patsopoulos, N.
    Lea, R.
    Lechner-Scott, J.
    Butzkueven, H.
    Jokubaitis, V.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 660 - 661
  • [48] Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
    Mark Sanford
    Drugs, 2014, 74 : 1411 - 1433
  • [49] Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
    Sanford, Mark
    DRUGS, 2014, 74 (12) : 1411 - 1433
  • [50] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
12345